Avantor Results Presentation Deck

Q4 performance Organic revenue growth Adjusted EBITDA growth Adjusted EPS growth Free cash flow Adjusted net leverage avantor™ 2.5% 15.6% 21.4% $314M 4.2X - Growth driven by Biopharma and ATAM -~4.6% core growth; -2.1% COVID-19 headwinds - Mix, inflation management and productivity Over 150 bps margin expansion including ~90 bps M&A impact Continued track record of execution Realization of benefits from interest and tax initiatives Lower working capital use partially offset by higher CapEx Lower interest from refinancing activities 3.1X excluding Masterflex leverage, down from 3.5X at Q3'21 Committed to 2-4X target leverage 4

View entire presentation